UC joins clinical trial to test treatment for abdominal injury
Injectable foam provides more time to get patients to life-saving surgery
Researchers at the University of Cincinnati are part of a clinical study for ResQFoam, a new device for the treatment of life-threatening abdominal internal bleeding. UC Medical Center is one of a handful of Level I Trauma Centers in the United States selected to participate in the multicenter Reducing Exsanguination Via In‐Vivo Expandable Foam (REVIVE) study.
ResQFoam is an injectable biomaterial that expands within the abdomen, providing pressure on internal organs to stop bleeding. That provides enough time to get the patient into the operating room, where the foam is easily removed prior to surgery.
The objective of the REVIVE study is to demonstrate the safety, effectiveness and benefit-risk profile of ResQFoam for the in-hospital treatment of severe internal abdominal bleeding and shock as the result of a traumatic injury.
We hope to demonstrate that this foam can safely and effectively be used to help save lives, both in the hospital and on the battlefield
Timothy Pritts, MD
ResQFoam was developed by Arsenal Medical, a medical technology company, with funding from the U.S. Department of Defense.
Patients enrolled in this study will be closely monitored for the first 30 days of their hospital visit. Pritts and his team will examine patient outcomes to determine the risks and benefits of the device in trauma patients.
The trauma physician will determine if incoming patients are possible candidates for this study and will enroll the patient if they are considered a good candidate. Unlike traditional clinical studies, this study will require the physicians to begin experimental emergency treatment without first obtaining an informed consent from the patient or a legal representative and/or family member.
All reasonable attempts will be made to contact a family member to discuss this study and obtain their permission for the patient to be in the study. All studies are voluntary and the patient or family members can decide at any time to withdraw from the study if they choose. Those who do not wish to take part in the study may opt out by requesting an embossed wristband.
“We hope to demonstrate that this foam can safely and effectively be used to help save lives, both in the hospital and on the battlefield,” said Timothy Pritts, MD, professor in the Division of Trauma Critical Care and Acute Care Surgery in the Department of Surgery at the UC College of Medicine and chief of the section of general surgery at UC Medical Center, and principal investigator of the study.
Within 30 minutes of arrival in the emergency department, a determination will be made to enroll a patient in the study. At that point, enrolled participants will receive an abdominal injection of two liquid polymers that react when they come in contact with each other, forming a foam that rapidly expands and molds to the anatomy. It is easily removed when the patient undergoes surgery to repair the traumatic injury. Those not enrolled in the study will receive current standard treatment for abdominal traumatic injuries.
Anyone with questions regarding this study or who would like to obtain an embossed wristband to opt out of the trial can contact the REVIVE Study Hotline at 513-558-6332 or at REVIVE@uc.edu.
Lead Photo of Timothy Pritts, MD/Colleen Kelley/UC Marketing + Brand
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Women consistently experience more pain than men across 11 body parts
October 12, 2026
A large global study spanning 118 countries, published in Nature Medicine, has found that women consistently report more pain than men across 11 bodily sites, including the back, head, face, knees, chest, abdomen and hips. The study also found that, across sexes, the sharpest increases in self-reported pain tend to occur before age 55. These findings may inform a new approach to chronic pain prevention and management throughout the lifespan. Shuchita Garg, MD, an associate professor of clinical medicine at the University of Cincinnati College of Medicine, Division of Chronic Pain, within the Department of Anesthesia, and the medical director of the UC Medical Center Pain Clinic, who was not involved in this study, commented on the findings for Medical News Today (MNT).
2026 Daniel Drake Medals awarded to three pioneering physician-scientists
October 12, 2026
The University of Cincinnati College of Medicine awards its highest honor, the 2026 Daniel Drake Medal, to three leaders in transplantation medicine, rare lung disease and heart health.
UC researcher to launch national study with $2.5 million NIH grant
October 9, 2026
A University of Cincinnati researcher has received a $2.5 million National Institutes of Health grant to conduct research during the next five years. Natalie Kreitzer, MD, a University of Cincinnati College of Medicine physician-researcher, received an R01 independent research grant from the NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development. The funding will support a test program for caregivers of patients with traumatic brain injury, as reported by the Cincinnati Business Courier.